ZSAN Zosano Pharma Corporation

+0.04  (+1%)
Previous Close 3.06
Open 3.13
Price To Book 5.74
Market Cap 54,941,421
Shares 17,723,039
Volume 38,053
Short Ratio
Av. Daily Volume 541,324

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial data due released February 13, 2017 - primary endpoints met.
Phase 2 data released September 2015. Considering Phase 3 initiation in 2016
Severe hypoglycemia
NDA filing due 4Q 2019. Phase 3 safety data released February 21, 2019.
Qtrypta (M207)

Latest News

  1. Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta™
  2. Zosano Pharma Reports First Quarter 2019 Financial Results
  3. Zosano Pharma Corp. to Host Earnings Call
  4. Zosano Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
  5. Zosano Pharma to Host Conference Call on First Quarter 2019 Financial Results and Provide Operational Update
  6. Zosano Pharma Corporation (NASDAQ:ZSAN): Immense Growth Potential?
  7. Zosano Announces the Publication of an Analysis of Acute Treatments for Migraine in Headache: The Journal of Head and Face Pain
  8. Zosano Announces Pricing of Public Offering of Common Stock
  9. Zosano Pharma Announces Proposed Public Offering of Common Stock
  10. Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results
  11. Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference
  12. Zosano Pharma to Host Conference Call on Fourth Quarter and Full Year 2018 Financial Results and Provide Operational and Strategic Update
  13. Detailed Research: Economic Perspectives on Zosano Pharma, Appian, Ross Stores, Alleghany, ZAGG, and Lindsay — What Drives Growth in Today's Competitive Landscape
  14. Four Healthcare Stocks Looking to Close Out a Strong Week
  15. FDA Events Can Send Stocks Soaring: Here's One That Absolutely No One Is Talking About
  16. Watch These Tech Stocks Push The Limit
  17. What Kind Of Shareholder Owns Most Zosano Pharma Corporation (NASDAQ:ZSAN) Stock?
  18. Zosano Announces Completion of the Final Milestone in the Long-Term Safety Study of Qtrypta™ for the Acute Treatment of Migraine Disease
  19. Zosano Announces Publication of Positive Data on Qtrypta’s™ Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines